Xenon Pharmaceuticals (XENE) Cash from Operations (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Cash from Operations data on file, last reported at 88897000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations fell 44.19% year-over-year to 88897000.0 in Q1 2026; TTM through Mar 2026 was 306363000.0, a 55.63% decrease from a year earlier, with the FY2025 full-year figure at 279118000.0, down 53.88% from the prior year.
• Cash from Operations for Q1 2026 stood at 88897000.0, down from 81481000.0 in the prior quarter.
• Over the last five years, Cash from Operations for XENE reached as high as 16868000.0 in Q2 2022 and fell as low as 88897000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 47149647.06 across 5 years, with a median of 46187000.0 in 2024.
• Across the five-year window, Cash from Operations grew 11.01% in 2022 and plunged 106.19% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 35330000.0 in 2022, then declined by 0.2% to 35401000.0 in 2023, then sank by 53.63% to 54385000.0 in 2024, then tumbled by 49.82% to 81481000.0 in 2025, then slipped by 9.1% to 88897000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 88897000.0 in Q1 2026, 81481000.0 in Q4 2025, and 71752000.0 in Q3 2025.